Stay updated on AXS-12 in Narcolepsy: Efficacy & Safety - Clinical Trial

Sign up to get notified when there's something new on the AXS-12 in Narcolepsy: Efficacy & Safety - Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AXS-12 in Narcolepsy: Efficacy & Safety - Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the efficacy or safety assessment of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness in a Phase 3 trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:30.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying age range, primary diagnosis, and compliance requirements, whereas previously no information was provided.
    Difference
    8%
    Check dated 2024-05-22T20:59:57.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:45:22.000Z thumbnail image

Stay in the know with updates to AXS-12 in Narcolepsy: Efficacy & Safety - Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AXS-12 in Narcolepsy: Efficacy & Safety - Clinical Trial page.